The AMPD1 Knouckout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the AMPD1 gene. This heterogeneous pool of edited cells provides a loss-of-function model for studying adenosine monophosphate deaminase 1 (AMPD1) in a human near-haploid background, circumventing the need for clonal isolation and preserving diverse genetic modifications. It serves as a robust system for dissecting purine metabolism and energy homeostasis pathways.
The HAP1 host line is a near-haploid human myeloid leukemia cell line derived from the KBM-7 line, originating from a patient with chronic myeloid leukemia. These cells exhibit an adherent, fibroblast-like morphology and maintain a single copy of most chromosomes, greatly simplifying gene-editing outcomes and phenotype interpretation. Their haploid nature minimizes complementary allele interference, making HAP1 a preferred model for high-confidence genetic screens and functional studies of metabolic enzymes and signaling factors implicated in cancer.
AMPD1 encodes the muscle-specific isoform of AMP deaminase, which catalyzes the irreversible deamination of AMP to IMP, liberating ammonia. This reaction is essential for buffering the adenylate energy charge during periods of high ATP turnover, such as in skeletal muscle contraction. AMPD1 activity is directly regulated by the cellular energy state: allosterically activated by AMP and inhibited by ATP, thus linking it intimately with AMPK signaling and cellular energy sensing. The resulting IMP feeds into purine salvage and can further contribute to fumarate generation via the TCA cycle. Key interacting molecules include calmodulin and other AMPD isoforms, positioning AMPD1 at a nexus of energy metabolism, nucleotide balance, and signal transduction.
In the context of HAP1 cells, AMPD1 knockout provides a defined genetic background to investigate purine nucleotide interconversion and metabolic stress responses. The near-haploidy allows unambiguous attribution of phenotypic changes to AMPD1 loss, enabling precise measurements of adenine nucleotide pools, IMP production, and downstream metabolic fluxes. This model is particularly suited for exploring how leukemia cells sustain energy charge under nutrient-limited conditions, and for identifying synthetic lethal interactions or metabolic dependencies that could be therapeutically exploited.
Researchers can leverage this polyclonal knockout population in enzyme kinetic assays, HPLC-based nucleotide quantification, and Seahorse extracellular flux analysis to assess glycolytic and mitochondrial respiration. Standard validation by western blotting and RT-qPCR confirms AMPD1 disruption, while immunofluorescence can monitor enzyme localization. Functional assays under metabolic challenges??such as glucose deprivation or oxidative stress??reveal the role of AMPD1 in cellular fitness. This tool supports drug screening for myoadenylate deaminase deficiency, metabolic flux analysis, and studies of purine-related disorders. For additional technical information, please contact Ascent Research.
